Quintrio
Home

SERVICES-HEALTH SERVICES

Omada Health, Inc. Common Stock

OMDA

Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.

Last trade $14.10
Day change -$0.395 (-2.73%)
Day range $14.05 – $14.49
Volume 321,220
Market cap $899M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$898.93M
Price / earnings
64.05×
Price / book
3.29×
Price / sales
2.7×
EV / sales
1.97×
EV / EBITDA
41.03×

Profitability

Earnings per share
$0.23
Return on assets
4.03%
Return on equity
5.14%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.18×
Quick ratio
4.11×
Cash ratio
3.23×

Cash flow

Price / cash flow
31.33×
Price / free cash flow
31.93×
Free cash flow
$28.15M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for OMDA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025
Revenue$91.31M$87.84M$78.05M$75.85M$68.03M$61.37M
Cost of revenue$22.02M$24.05M$29.36M$22.18M$22.96M$21.07M
Gross profit$69.28M$63.79M$48.69M$53.66M$45.07M$40.31M
Selling, general and administrative$49.19M$45.61M$40.78M$38.83M$37.28M$34.63M
Research and development$15.27M$14.63M$12.7M$11.55M$10.3M$10.02M
Total operating expenses$64.46M$60.24M$53.47M$50.38M$47.58M$44.65M
Operating income$4.82M$3.55M-$4.78M$3.28M-$2.51M-$4.34M
Interest expense-$262K-$14K-$18K-$13K-$353K-$1.09M
Income before taxes$6.55M$5.29M-$2.97M$5.16M-$3.18M-$5.31M
Income taxes$0$0$0$0$0$0
Net income$6.55M$5.29M-$2.97M$5.16M-$3.18M-$5.31M
Net income attributable to common shareholders$6.55M$5.29M-$2.97M$5.16M-$3.18M-$5.31M
EBITDA$9.4M$5.13M-$3.27M$4.73M$1.31M-$2.99M
Basic earnings per share$0.11$0.09-$0.05$0.09-$0.06-$0.24
Diluted earnings per share$0.10$0.08-$0.05$0.09-$0.06-$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Omada: 3 Key Takeaways for Long-Term Investors

Omada Health reported strong Q3 2026 results with 34% year-over-year revenue growth to $91 million and raised full-year guidance. The company achieved record member retention of 2.5 years average tenure and reduced care delivery costs to an all-time low of $81 per member through AI automation. Omada's flexible GLP-1 product strategy positions it to benefit regardless of employer coverage decisions, while its $243 million cash position with no debt provides financial strength for expansion.

Zacks Investment Research

Compared to Estimates, Omada Health, Inc. (OMDA) Q3 Earnings: A Look at Key Metrics

Omada Health reported Q3 2026 revenue of $91.31 million, up 34.2% year-over-year, beating the consensus estimate of $85.75 million by 6.48%. EPS came in at $0.17, significantly exceeding the $0.09 estimate by 88.89%. However, total members declined to 1.1 million from the estimated 1.12 million. The stock has a Zacks Rank #3 (Hold) rating and has underperformed the broader market, down 7% over the past month.

Zacks Investment Research

Omada Health, Inc. (OMDA) Q3 Earnings and Revenues Beat Estimates

Omada Health (OMDA) reported Q3 2026 earnings of $0.17 per share, beating consensus estimates of $0.09 by 88.89%, with revenues of $91.31 million exceeding expectations by 6.48%. The company has outperformed market estimates four consecutive quarters. However, the stock received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market. Peer company LifeMD is expected to report a quarterly loss of $0.14 per share with declining revenues.

GlobeNewswire Inc.

New York Academy of Medicine Names Leaders from Hospital for Special Surgery and Omada Health to Board of Trustees

The New York Academy of Medicine announced two new Board of Trustees members: Ann Marie McDonald, senior vice president and chief nursing executive at Hospital for Special Surgery, and Thomas Tsang, chief medical officer at Omada Health. Both leaders bring extensive expertise in healthcare quality, clinical operations, and technology-enabled care delivery.

GlobeNewswire Inc.

Omada Health to Participate in Canaccord Genuity’s 46th Annual Growth Conference

Omada Health announced that senior management will participate in Canaccord Genuity's 46th annual Growth Conference in Boston on August 11, 2026, with a fireside chat. The company provides virtual healthcare services for chronic conditions and has served over two million members across 2,000+ employers and health plans.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.